Usefulness of thrombolytic therapy with low doses of streptokinase in acute myocardial infarction;Utilidad de la terapia trombolítica con estreptokinasa a dosis baja en infarto agudo del miocardio

Revista Medica de Chile

Volumn 134, Issue 10, 2006, Pages 1249-1257

  Carlos Raffo, G ^a   Jorge Bartolucci, J ^a,f   Ramon Corbalan H ^b   Mauricio Aninat, H ^a   Humberto Torres, H ^a   Juan Carlos Prieto, D ^c   Fernando Lanas, Z ^d   Eduardo Chavez S ^e   Francisco Cumsille, G ^e   Carolina Nazzal, N ^e  

^a Hospital Dr Gustavo Fricke   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^d Hospital Regional de Temuco   (Chile)

^e Asistencia Pública de Santiago ^*

^f CLÍNICA SANTA MARÍA   (Chile)

Author keywords

Myocardial infarction; Streptokinase; Thrombolytic therapy

Indexed keywords

CREATINE KINASE; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE;

AGED; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PAIN ASSESSMENT; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

AGED; CHI-SQUARE DISTRIBUTION; CREATINE KINASE; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PAIN MEASUREMENT; PROSPECTIVE STUDIES; RISK FACTORS; STREPTOKINASE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 33845735466     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. The Gusto Investigators. An international trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
2. Ross AM. New plasminogen activators. A clinical review. Clin Cardiol 1999; 22: 165-71.
3. Ross AM, Coyne K, Moreya E, Reiner JS, Greenhouse SW, Walker PL, Somoons ML, Draoui YC, Califf RM, Topol EJ, Van De Werf F, Lundergan CF, for the Gusto-I Angiographic Investigators. Extended mortality benefit of early postinfarction reperfusion. Circulation 1998; 97: 1549-56.
4. Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, Ross AM, for the GUSTO-I Investigators. Link between the angiographic substudy and mortality outcomes in the large randomized trial of myocardial reperfusion. Circulation 1995; 91: 1923-8.
5. Antman EM, Giugliano RP, McCabe CH, Gibson M, Adgey AJJ, Ghali M, Coussement P, Anderson KM, Scherer J, Van De Werf F, Braunwald E, for the timi 14 investigators. Abciximab (reoPro) potentiates thrombolysis in ST elevation myocardial infarction: Results of TIMI 14 trial. J Am Coll Cardiol 1998; 31(suppl): 191A.
6. Schroeder B, Von Leitnere, Linder T. Intravenous short-time thrombolysis in acute myocardial infarction (Abstract). Circulation 1981; 64: (suppl IV) 10.
7. GISSI (Gruppo Italiano por lo Studio della Streptochinasi nell'Infarto Miocardio). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; I: 397-401.
8. ISIS-2. Collaborative Group (Second International Study of Infarct Survival). Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17.189 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
9. ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity and infarct size at 21 days. N Engl J Med 1986; 314: 1465-71.
10. Gaffney P, Joe F, ROwe E, Whitaker A. The influence of various combination of plasminogen and streptokinase on fibrinolysis. Rate Study. Haemostasis 1981; 10: 304-14.
11. Spann J, Sherry S. Coronary thrombolysis for evolving myocardial infarction. Drugs 1984; 28: 465-83.
12. Aninat M, Col J, Rankin J, Jacquet L, Anwar A, Etienne J. Infarto agudo del miocardio: Eficacia trombolítica de 500.000 U de estreptokinasa asociada a heparina. Rev Méd Chile 1990; 118: 862-67.
13. Eisenberg P, Sherman L, Jaffe A. Paradoxical elevation of fibrinopeptide A after streptokinase: Evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987; 10: 527-9.
14. Lew A, Cercet B, Hord H, Shah P, Ganz W. Usefulness of residual plasma fibrinogen after intravenous streptokinase for predicting delay or failure of reperfusion in acute myocardial infarction. Am J Cardiol 1986; 58: 680-5.
15. Grupo de Estudios Multicéntricos del Infarto al Miocardio (GEMI). ¿Es posible para la cardiología chilena realizar estudios multicéntricos? Revista Chilena de Cardiología 1993: 12: 153-60.
16. Corbalán R, Prieto J, Chávez E, Nazzal C, Cumsille F, Krucoff M. Bedside markers of coronary artery patency and short-term prognosis of patients with acute myocardial infarction and thrombolysis. Am Heart J 1999; 138: 533-9.
17. Simoons ML, Maggioni AP, Knatterud G, Leimberger JD, De Jaegere P, Van Domburg R, Boersma E et als. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. Lancet 1993; 342: 1523-8.
18. st International Congress on Heart Diseases. New Trends in Research, Diagnosis and Treatment. May 18, 1999, Washington, DC. Vol 75 (11) Nov 2000: 1185-92.
19. Tatu-Chitoiu G, Teodorescu C, Fluerasu A, Cäpraru P, Guran M, Dan M et al. Accelerated streptokinase a new thrombolytic regimen in acute myocardial infarction. Rom J Intern Med 1998; 36: 183-96.
20. Tatu-Chitoiu G, Orha I, Teodorescu C, Fluerasu A, Serban L, Bumbu A. Rapid infusion of streptokinase standard dose in acute myocardial infarction is followed by a higher rate of coronary reperfusion than standard protocol. Rom J Intern Med 1997; 35: 47-54.
21. Srimahachota S, Sangwatanaroj S, Boonyaratavej S, Suitichaiyakul T, Ngarmukos P. Efficacy of rapid infusion of streptokinase in patients with acute myocardial infarction. J Med Assoc Thai 2000; 83: 8-12.
22. Antman EM, McCabe CH, Gurfinkel EP, Turpic AG, Bernink PJ, Salem D, Bayes De Luna A et al, for the TIMI 11B Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial. Circulation 1999; 100: 1593-601.
23. Antman EM, Cohen M, Radley R, McCabe C, Rush J, Premmereur J et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q myocardial infarction: the TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602-8.
24. Glick A, Kornowski R, Michowich Y, Koifman B, Roth A, Lamiado S et al. Reduction of reinfarction and angina with use of low-molecular-weigth heparin after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996; 77: 1145-8.